The case for the use of pooled donors in the manufacture of allogeneic cell therapies

Cell & Gene Therapy Insights 2021; 7(2), 327–335


Published: 24 March 2021
Expert Insight
Benjamin Weil

Cell and gene therapy (CGT) continues to be an expanding field of biotech, however, current therapies are frequently associated with complex manufacture and distribution platforms which result in high costs of goods. To provide the benefits from economies of scale, quality control batch testing, and an ‘off-the-shelf’ supply model, allogeneic treatments are attractive where possible. This Expert Insight article will assess both the bioprocess and therapeutic dependency of donor material, and present pooled donor therapies as a necessary consideration for commercial CGT relevance.